| Título : |
Cost effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Colombia |
| Tipo de documento : |
documento electrónico |
| Autores : |
Fabián Juliao Baños, |
| Fecha de publicación : |
2022 |
| Títulos uniformes : |
PharmacoEconomics - Open
|
| Idioma : |
Inglés (eng) |
| Resumen : |
Objective: The aim of this study was to evaluate the cost effectiveness of tofacitinib versus other treatment options currently available in Colombia in naïve to biologics (first-line) and exposed to biologics (second-line) patients with moderate to severe active ulcerative colitis (UC). Methods: A Markov model was constructed with 8-week cycles, simulating a cohort of patients in a 5-year time horizon. The health states included remission, treatment response, active UC, and colectomy. The transition probabilities for the induction and maintenance phase were obtained from a network meta-analysis, and effectiveness was measured using quality-adjusted life-years (QALYs). Unit costs were derived from official national sources. Results: For first line, the incremental cost-effectiveness ratio (ICER) per QALY was $883 for tofacitinib and $3619 for infliximab, compared with adalimumab. Sensitivity analysis showed that tofacitinib is cost effective in 45% of the iterations, adalimumab in 5%, and infliximab in 50%. Meanwhile, the ICER of adalimumab was $14,927 compared with tofacitinib in second-line treatment. In the sensitivity analysis, tofacitinib was cost effective in 64% of the iterations, followed by adalimumab in 36%. Infliximab and golimumab were not included due to data limitations in the network meta-analysis of second-line treatment. Conclusion: The analysis suggests that in Colombia, treatment with tofacitinib for patients with moderate-to-severe UC is a cost-effective option in both lines compared with other treatment options. |
| Mención de responsabilidad : |
Fabio Gil, Fabian Juliao-Baños, Luisa Amador, Natalia Castano & Juan Manuel Reyes |
| Referencia : |
Pharmacoecon Open. 2022 Nov;6(6):837-846. |
| DOI (Digital Object Identifier) : |
10.1007/s41669-022-00360-4 |
| PMID : |
35943702 |
| En línea : |
https://link.springer.com/article/10.1007/s41669-022-00360-4 |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6083 |
Cost effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Colombia [documento electrónico] / Fabián Juliao Baños, . - 2022. Obra : PharmacoEconomics - OpenIdioma : Inglés ( eng) | Resumen : |
Objective: The aim of this study was to evaluate the cost effectiveness of tofacitinib versus other treatment options currently available in Colombia in naïve to biologics (first-line) and exposed to biologics (second-line) patients with moderate to severe active ulcerative colitis (UC). Methods: A Markov model was constructed with 8-week cycles, simulating a cohort of patients in a 5-year time horizon. The health states included remission, treatment response, active UC, and colectomy. The transition probabilities for the induction and maintenance phase were obtained from a network meta-analysis, and effectiveness was measured using quality-adjusted life-years (QALYs). Unit costs were derived from official national sources. Results: For first line, the incremental cost-effectiveness ratio (ICER) per QALY was $883 for tofacitinib and $3619 for infliximab, compared with adalimumab. Sensitivity analysis showed that tofacitinib is cost effective in 45% of the iterations, adalimumab in 5%, and infliximab in 50%. Meanwhile, the ICER of adalimumab was $14,927 compared with tofacitinib in second-line treatment. In the sensitivity analysis, tofacitinib was cost effective in 64% of the iterations, followed by adalimumab in 36%. Infliximab and golimumab were not included due to data limitations in the network meta-analysis of second-line treatment. Conclusion: The analysis suggests that in Colombia, treatment with tofacitinib for patients with moderate-to-severe UC is a cost-effective option in both lines compared with other treatment options. |
| Mención de responsabilidad : |
Fabio Gil, Fabian Juliao-Baños, Luisa Amador, Natalia Castano & Juan Manuel Reyes |
| Referencia : |
Pharmacoecon Open. 2022 Nov;6(6):837-846. |
| DOI (Digital Object Identifier) : |
10.1007/s41669-022-00360-4 |
| PMID : |
35943702 |
| En línea : |
https://link.springer.com/article/10.1007/s41669-022-00360-4 |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6083 |
|  |
Inicio
Clasificado(s) por (Año de edición descendente) Refinar búsquedaCost effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Colombia / Fabián Juliao Baños
